RegeneRx Biopharmaceuticals, Inc.

Neurotrophic Keratitis, a rare eye disease affecting corneal sensitivity, can lead to vision loss without proper treatment. Treatments include topical antibiotics, keratoplasty, and Oxervate, the first FDA-approved drug for this condition. The COVID-19 pandemic impacted the market, reducing demand and supply. North America leads the market, with Asia Pacific expected to grow. Key factors driving market growth include increasing geriatric population and R&D investments. New therapies like Oxervate and collaborations aim to address unmet medical needs in ophthalmology.